- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03653273
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP) (STOP-I-SEP)
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Multiple sclerosis (MS) usually evolves over decades and can present several phenotypes. Approximately 85% of newly diagnosed Multiple Sclerosis (MS) patients present the Relapsing-Remitting MS (RRMS) phenotype. After a mean time of approximatively 20 years, a large majority of these patients evolve to the so-called "Secondary Progressive MS" (SPMS) phase. SPMS is characterized by an irreversible disability progression not related to relapses, although relapses could be superimposed. Nevertheless, the shift in-between RRMS and SPMS is not clear. Different subtypes of SPMS have been recently defined by F Lublin et al. This classification takes into account persistent focal inflammatory activity (active vs inactive SPMS) along with disease progression (progressing vs non-progressing SPMS). In clinical routine, it is important to identify these stages of MS as they differently respond to the disease modifying therapies (DMTs).
Introducing DMTs during the RRMS phase had consistently demonstrated a significant impact on the annual relapse rate (ARR) and on the short-term disability progression. Conversely, during the SPMS phase, the impact of DMTs remained uncertain on disability progression, especially in older patients, with "inactive" disease. As a matter of fact, the DMTs are considered to be anti-inflammatory by nature, but the focal inflammation reduces with age and disease duration.
In addition, the DMTs have side effects and cost approximately 10,000 euros per year and per patient. In this context, the usefulness of continuing DMTs in "inactive" SPMS patients older than 50 years is questionable.
In a preliminary retrospective study conducted at our Institute which enrolled 100 SPMS patients, the ARR remained stable 3 years after treatment withdrawal (0.07, 95% CI [0.05, 0.11]), relative to the 3 years prior to treatment withdrawal (0.12, [0.09, 0.16]). EDSS scores were available for 94 patients The percentage of patients experiencing a significant increase of their EDSS score during the 3 years after treatment withdrawal also remained stable compared to the 3 years prior treatment withdrawal. These preliminary data support the safety of DMTs withdrawal in selected SPMS patients. However, further prospective studies are needed to provide evidence-based guidelines for daily practice.
This randomized controlled clinical trial thus aims to compare SPMS patients older than 50 years without evidence of focal inflammatory activity for 3 years, stopping DMTs versus patients with the same criteria still receiving treatment. We hypothesize that stopping DMTs will not induce an increased risk of disability progression or relapse in SPMS patients but will improve their quality of life and have an impact on treatment-related costs.
So far, the impact of DMTs withdrawal in a selected SPMS population has not been explored. Having evidence-based recommendations on the treatment management of these patients is essential, considering the consequences in terms of disability, relapses, side effects, quality of life and costs. DMTs in MS are now available since 20 years, with an increasing number of approved molecules. As a matter of fact, this question concerns a large number of patients: a retrospective analysis of patients included in the Rennes EDMUS database allowed to identify 71 SPMS patients older than 50 years and without evidence of focal inflammatory activity for 3 years actually undergoing a DMT.
For evident conflict of interests, the pharmaceutical firms will not promote or fund clinical trials on treatment withdrawal. A randomized controlled study initiated by academia and financed by public funding should be performed to explore these questions. We will evaluate the impact of these changes from the patient and the health system's points of view. The results of this clinical trial will lead to a concrete change in clinical practice.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Anne KERBRAT, Dr
- Phone Number: +33 2 99 28 41 69
- Email: anne.kerbrat@chu-rennes.fr
Study Contact Backup
- Name: Gilles EDAN, Pr
- Phone Number: +33 2 99 28 41 22
- Email: gilles.edan@chu-rennes.fr
Study Locations
-
-
-
Angers, France
- Recruiting
- CHU Angers
-
Contact:
- Clarisse SCHERER-GAGOU, Dr
-
Bordeaux, France
- Active, not recruiting
- CHU de Bordeaux
-
Brest, France
- Recruiting
- CHU Brest
-
Contact:
- François ROUHART, Dr
-
Chartres, France
- Active, not recruiting
- CH de Chartres
-
Clermont-Ferrand, France
- Recruiting
- CHU Clermont-Ferrand
-
Contact:
- Pierre CLAVELOU, Pr
-
Créteil, France
- Active, not recruiting
- Hôpital Henri Mondor
-
Dijon, France
- Active, not recruiting
- CHU Dijon
-
Grenoble, France
- Recruiting
- CHU Grenoble
-
Contact:
- Olivier CASEZ, Dr
-
Libourne, France
- Active, not recruiting
- CH de Libourne
-
Lille, France
- Recruiting
- CHU Lille
-
Contact:
- Hélène ZEPHIR, Pr
-
Lille, France
- Recruiting
- Hôpital Saint Vincent de Paul
-
Contact:
- Arnaud KWIATKOWSKI, Dr
-
Principal Investigator:
- Arnaud KWIATKOWSKI, Dr
-
Lyon, France
- Recruiting
- Hospices Civils Lyon
-
Contact:
- Sandra Vukusic, Pr
-
Marseille, France
- Active, not recruiting
- AP-HM
-
Montpellier, France
- Recruiting
- CHU Montpellier
-
Contact:
- Pierre LABAUGE, Pr
-
Nancy, France
- Terminated
- CHU Nancy
-
Nantes, France
- Recruiting
- CHU Nantes
-
Contact:
- David LAPLAUD, Pr
-
Nice, France
- Recruiting
- CHU Nice
-
Contact:
- Christine LEBRUN-FRENAY, Pr
-
Nîmes, France
- Not yet recruiting
- CHU de Nîmes
-
Contact:
- Eric THOUVENOT, Pr
-
Paris, France
- Recruiting
- AP-HP (La Pitié Salpêtrière)
-
Contact:
- Céline LOUAPRE, Dr
-
Paris, France
- Terminated
- Fondation de Rothschild
-
Poissy, France
- Recruiting
- CH Poissy
-
Contact:
- Olivier HEINZLEF, Dr
-
Poitiers, France
- Terminated
- CHU Poitiers
-
Quimper, France
- Recruiting
- CH Quimper
-
Contact:
- Marc COUSTANS, Dr
-
Rennes, France
- Recruiting
- CHU Rennes
-
Contact:
- Anne Kerbrat, Dr
-
Strasbourg, France
- Recruiting
- CHU Strasbourg
-
Contact:
- Jérôme De Seze, Pr
-
Suresnes, France
- Active, not recruiting
- CH de Foch
-
Tours, France
- Recruiting
- Chu Tours
-
Contact:
- Anne-Marie GUENNOC, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients > 50 years old;
- Secondary progressive phenotype for at least 3 years; The secondary progressive phenotype will be defined as progressive deterioration of disability not due to relapse, with an increase of at least 1 EDSS point since the beginning of the progressive phase (or 0.5 EDSS point if EDSS score ≥ 5.5).
- Disease modifying therapy of MS for at least 3 years (interferon, glatiramer acetate, teriflunomide, dimethyl fumarate, cyclophosphamide, azathioprine, methotrexate, mycophenolate mofetil, rituximab, ocrelizumab); Both patients with the same DMT or with successive DMTs during 3 years can be included. It is important to note that patients could have been treated with fingolimod or natalizumab 2 or 3 years before inclusion, but not during the year before inclusion ;
- No evidence of focal inflammatory activity for at least 3 years (no clinical relapse and no gadolinium enhancement on an MRI scan);
- EDSS≥3.
Concomitant medications with Fampridine are allowed throughout the study, provided they have been introduced at least 1 months before inclusion.
Natalizumab and fingolimod during the year before inclusion were excluded because of the risk of recurrence of inflammatory activity or even rebound of inflammatory activity after withdrawal.
Both patients with the same DMT or with successive DMTs during 3 years can be included, as for example, cyclophosphamide is used for 1 or 2 years, sometimes followed by mycophenolate mofetil.
For Rituximab and Ocrelizumab, inclusion in STOP-I-SEP will be at 6 months from the last infusion to take into account the mode of action of these treatments and their specific administration scheme.
Exclusion Criteria:
- Patients treated with mitoxantrone or alemtuzumab, during the previous 3 years before inclusion;
- Patients treated with natalizumab or fingolimod during the year before inclusion;
- Change of disease modifying therapy of MS for less than a year
- Other neurological or systemic disease ;
- Incapacity to understand or sign the consent form ;
- Contraindication to MRI ;
- Pregnancy or breast-feeding ;
- Patient in another clinical trial
- Persons referred to in Articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the Public Health Code (eg minors, protected adults, …).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DMT withdrawal
DMT will be immediately stopped after randomization.These patients will be followed for 2 years.
|
Group 1 (DMT withdrawal) will not undergo any disease modifying treatments (DMT).
|
Active Comparator: DMT continuation
The previously established therapy will be continued at the same dose during two years.
|
Group 2 (DMT continuation) may undergo the DMT .
The therapy continued in this research is the one previously established, at the same dose, not implying additional precautions for use.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disability progression measured by EDSS
Time Frame: 24 months
|
Disability progression measured by the Percentage of patients experiencing disability progression (confirmed at 6 months) at 2 years. Disability progression will be defined as an increase in the EDSS of at least 1 point if the baseline EDSS was 5.5 or less, or 0.5 point if the Baseline EDSS was more than 5.5. |
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of Disability progression
Time Frame: 24 months
|
Disability progression measured by Time from DMT withdrawal to disability progression
|
24 months
|
Disability progression measured by composite score
Time Frame: 24 months
|
Disability progression measured by Change in a composite disability progression score (increase in the EDSS score, or an increase in the time to perform the timed 25-foot walk ≥ 20%, or an increase in the time to complete the 9-hole peg test ≥ 20%) confirmed at 6 months
|
24 months
|
Disability progression measured by SDMT
Time Frame: 24 months
|
Disability progression measured by Change in the SDMT score from baseline to 2-year
|
24 months
|
Percentage of patients with Relapse
Time Frame: 24 months
|
Relapses measured by Percentage of patients with at least one relapse from baseline to 2-year
|
24 months
|
Annualized relapse rate
Time Frame: 24 months
|
Relapses measured by Annualized relapse rate during 2-year
|
24 months
|
Time of Relapses
Time Frame: 24 months
|
Relapses measured byTime from DMT withdrawal to first relapse;
|
24 months
|
Percentage of patients with brain lesion
Time Frame: 24 months
|
Percentage of patients with one or more new or enlarging brain MRI (Magnetic Resonance Imaging) lesions from baseline to 2-year
|
24 months
|
Percentage of patients with gadolinium enhancing lesion
Time Frame: 24 months
|
Percentage of patients with at least one gadolinium enhancing lesion(s) at 6 months, and/or 1 year,and/or 2-year
|
24 months
|
Change in brain volume
Time Frame: 24 months
|
Change in brain volume from baseline to 2-year measured on MRI
|
24 months
|
Percentage of patients with no evidence of disease activity
Time Frame: 24 months
|
Percentage of patients with no evidence of disease activity (NEDA 3: no clinical relapse, no MRI activity, no disability progression) at 2-year
|
24 months
|
Percentage of patients who resume DMT in the treatment withdrawal group
Time Frame: 24 months
|
Percentage of patients who resume DMT in the treatment withdrawal group at 2-year
|
24 months
|
Quality of life measured by SEP-59 score
Time Frame: 24 months
|
Change in the SEP-59 score from baseline to 2-year;
|
24 months
|
Quality of life measured by EQ-5D score
Time Frame: 24 months
|
Change in the EuroQOL EQ-5D from baseline to 2-year;
|
24 months
|
Medico economic impact
Time Frame: 24 months
|
Incremental Cost Effectiveness Ratio (ICER) defined as the cost for QALY gained in "treatment withdrawal group" versus "treatment continued group"
|
24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anne KERBRAT, Dr, CHU Rennes - National Headache Center
- Principal Investigator: Clarisse SCHERER-GAGOU, Dr, University Hospital, Angers
- Principal Investigator: Jean PELLETIER, Pr, AP-HM
- Principal Investigator: Céline LOUAPRE, Dr, AP-HP La Pitié Salpêtrière
- Principal Investigator: Pierre CLAVELOU, Pr, University Hospital, Clermont-Ferrand
- Principal Investigator: Thibault MOREAU, Pr, CHU Dijon
- Principal Investigator: Olivier CASEZ, Dr, University Hospital, Grenoble
- Principal Investigator: Hélène ZEPHIR, Pr, CHU Lille
- Principal Investigator: Sandra VUKUSIC, Pr, Hospices Civils de Lyon
- Principal Investigator: Pierre LABAUGE, Pr, University Hospital, Montpellier
- Principal Investigator: Guillaume MATHEY, Dr, CHU Nancy
- Principal Investigator: Christine LEBRUN-FRENAY, Pr, CHU Nice
- Principal Investigator: Olivier HEINZLEF, Dr, CH Poissy
- Principal Investigator: Jean-Philippe NEAU, Pr, CHU Poitiers
- Principal Investigator: Marc COUSTANS, Dr, CH Quimper
- Principal Investigator: Jérôme DE SEZE, Pr, CHU Strasbourg
- Principal Investigator: Anne-Marie GUENNOC, Dr, Chu Tours
- Principal Investigator: Caroline BENSA-KOSCHER, Dr, Fondation de Rothschild
- Principal Investigator: Eric THOUVENOT, Pr, Centre Hospitalier Universitaire de Nimes
- Principal Investigator: Alain CREANGE, Pr, CH Henri Mondor
- Principal Investigator: Arnaud KWIATKOWSKI, Dr, Hôpital Saint Vincent de Paul
- Principal Investigator: Aurore JOURDAIN, Dr, CHU Brest
- Principal Investigator: David LAPLAUD, Pr, Nantes University Hospital
- Principal Investigator: Aurelie RUET, Pr, University Hospital, Bordeaux
- Principal Investigator: Jérôme GRIMAUD, Dr, CH de Chartres
- Principal Investigator: Maia TCHIKVILADZE, Dr, CH Foch
- Principal Investigator: Philippe CASENAVE, Dr, CH de Libourne
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 35RC17_8842_STOP-I-SEP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on DMT withdrawal
-
The University of Hong KongTung Wah Group of HospitalsCompleted
-
Changhai HospitalShaanxi Provincial People's Hospital; Qinghai People's Hospital; The First Affiliated... and other collaboratorsCompleted
-
Amasya UniversityCompletedSchizophrenia | Disabilities Mental | Negative Symptoms in Schizophrenia | Dance TherapyTurkey
-
Washington University School of MedicineTerminatedColorectal Cancer | Rectal Cancer | Colon CancerUnited States
-
The Catholic University of KoreaCompletedAdenoma of Large Intestine
-
Yale UniversityActive, not recruitingDepression | Major Depressive DisorderUnited States
-
Centre de Recherche de l'Institut Universitaire...Completed
-
Max NieuwdorpNot yet recruitingUpper Respiratory Tract InfectionNetherlands
-
Beckley Psytech LimitedCompletedPharmacokinetics in Healthy AdultsUnited Kingdom
-
Changhai HospitalThe Second Hospital of Hebei Medical University; Air Force Military Medical... and other collaboratorsRecruitingColorectal Sessile Serrated LesionChina